Phase IIa Study of Nimotuzumab to Treat Colorectal Cancer
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
Nimotuzumab is an IgG1 humanized monoclonal antibody that recognized an epitope located in
the extra cellular domain of the human epidermal growth factor receptor (EGFR). Clinical
efficacy has been shown in adult with head and neck cancer. The study assessed the safety,
and efficacy of the combination of Nimotuzumab administered concomitantly with chemotherapy
in patients with advanced colorectal cancer.